Can a new injection slow stomach emptying to curb obesity?

NCT ID NCT07738614

First seen Jul 31, 2026 ยท Last updated Jul 31, 2026

Summary

This early-stage trial is testing whether an investigational drug called eloralintide can slow down how quickly the stomach empties, which may help people feel fuller longer and support weight management. The study involves about 56 adults who are overweight or have obesity but are otherwise healthy. Participants receive multiple doses of the drug or a placebo, and researchers measure stomach emptying using a standard test with acetaminophen, along with checking the drug's safety and how it moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Eloralintide (also known as LY3841136), an investigational drug given by injection
What this could lead to
If successful, this could lead to a new treatment option for obesity that helps control appetite and weight by slowing stomach emptying.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The drug may also cause side effects or fail to show meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICON Early Phase Services

    San Antonio, Texas, 78209, United States

  • Lilly Centre for Clinical Pharmacology

    Singapore, 138623, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.